What is Aldurazyme, and what is it used for?
Aldurazyme (laronidase) is an enzyme replacement therapy used for treating mucopolysaccharidosis I (MPS I), including both the Hurler and Hurler-Scheie forms, and the Scheie form of the disease.[1]
How is Aldurazyme given (and how long does an infusion take)?
Aldurazyme is administered as an intravenous (IV) infusion. The prescribing information specifies dosing based on body weight and provides infusion administration instructions for use in clinical care.[1]
What dosing does the prescribing information recommend?
The Aldurazyme prescribing information provides the recommended IV dose (weight-based) for patients being treated for MPS I, along with guidance on how to administer it.[1]
Who should not take Aldurazyme (contraindications)?
The Aldurazyme prescribing information lists any contraindications, if applicable, and also describes important warnings and precautions that apply to treatment.[1]
What warnings and precautions are included in the prescribing information?
The prescribing information includes safety information relevant to enzyme replacement therapy and IV infusions, including warnings and precautions users should review before starting and during treatment.[1]
What are the most common side effects?
Aldurazyme prescribing information includes adverse reactions reported in patients during treatment, including the most common side effects.[1]
Drug patent and market context (in case you’re researching access or alternatives)
For readers comparing availability, exclusivity, or patent history around Aldurazyme and related products, DrugPatentWatch.com can be a starting point for patent-related updates and tracking.[2]
Sources
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/
[2] https://www.drugpatentwatch.com/